Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Recursion Pharmaceuticals Inc Cl A (NQ: RXRX )

8.065 +1.475 (+22.38%)
Streaming Delayed Price Updated: 12:48 PM EST, Dec 6, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 21,915,135
Open 6.800
Bid (Size) 8.060 (19)
Ask (Size) 8.070 (53)
Prev. Close 6.590
Today's Range 6.696 - 8.150
52wk Range 5.600 - 15.74
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Ulta Beauty Posts Upbeat Results, Joins Asana, Lululemon, Hewlett Packard Enterprise And Other Big Stocks Moving Higher On Friday
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga

Performance

YTD
-18.29%
-18.29%
1 Month
+18.26%
+18.26%
3 Month
+30.71%
+30.71%
6 Month
-10.49%
-10.49%
1 Year
+8.69%
+8.69%

More News

Read More
Artificial Intelligence (AI) Redefining Medical Diagnostics Industry That’s Expected to be a $7.2 Billion Market by 2029
Via FinancialNewsMedia
Topics Artificial Intelligence
Exposures Artificial Intelligence
(RXRX) - Analyzing Recursion Pharmaceuticals's Short Interest
Via Benzinga
A Closer Look at 4 Analyst Recommendations For Recursion Pharmaceuticals
Via Benzinga
Berkshire Hathaway Isn't the Only Publicly Traded Company That Buys Stocks. These 3 Tech Giants Also Have Stock Portfolios.
Via The Motley Fool
Recursion announces first patient dosed in Phase 1/2 clinical study of REC-1245, a potential first-in-class, RBM39 degrader for Biomarker-Enriched Solid Tumors and Lymphoma
From Recursion Pharmaceuticals, Inc.
Via GlobeNewswire
XPeng, NovoCure, Merus, Gap And Other Big Stocks Moving Higher On Monday
Via Benzinga
Peering Into Recursion Pharmaceuticals's Recent Short Interest
Via Benzinga
Recursion to Report Third Quarter 2024 Business Updates and Financial Results on November 6th
From Recursion Pharmaceuticals
Via GlobeNewswire
NVIDIA Invested in These 2 AI Stocks, Should You?
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence Product Safety
Jim Cramer: Reddit Is 'Fabulous,' Dow Is A 'Tough' One
Via Benzinga
Topics Stocks
Exposures US Equities
Cathie Wood Sees $400B Opportunity In Biologics — How Have Her Bets Fared?
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
2 Innovative Stocks That Could Deliver Outsize Returns
Via The Motley Fool
Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery
From Recursion Pharmaceuticals, Inc.
Via GlobeNewswire
Nvidia Reveals 3.6% Stake In Applied Digital, Stock Soars
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Nvidia Discloses Stake In Applied Digital, Keeps Arm, SoundHound Stakes
Via Investor's Business Daily
Recursion and Exscientia Shareholders Approve the Proposed Combination
From Recursion Pharmaceuticals
Via GlobeNewswire
Recursion Announces the Release of OpenPhenom-S/16 in Google Cloud’s Model Garden
From Recursion Pharmaceuticals, Inc.
Via GlobeNewswire
MARA Holdings, RadNet, Bit Digital, Coinbase And Other Big Stocks Moving Higher On Monday
Via Benzinga
Recursion Provides Business Updates and Reports Third Quarter 2024 Financial Results
From Recursion Pharmaceuticals
Via GlobeNewswire
10 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Is Recursion Pharmaceuticals a Millionaire-Maker Stock?
Via The Motley Fool
Cathie Wood's Ark Innovation, Genomic ETFs Celebrate 10 Years: How Annual Returns Stack Up Against S&P 500
Via Benzinga
Topics ETFs Stocks
Exposures US Equities
3 Key Trends That Are Bullish for Recursion Pharmaceuticals Stock
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.